TB preventive therapy is mandatory for TBI-IMID patients undergoing treatment with bDMARDs and tsDMARDs such as TNF-α blockers, anti-IL-6, and JAKs inhibitors, considered drugs at high risk of TB reactivation (19). This evidence concerns the gene TNF and tuberculosis.